3.92
6.67%
-0.28
Handel nachbörslich:
3.96
0.04
+1.02%
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada
Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St
Exagen stock soars to 52-week high, hits $3.79 - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK
Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com
What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Australia
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Ch - GuruFocus.com
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... - Yahoo Finance
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... By GuruFocus - Investing.com Canada
Exagen Inc. Reports Q3 2024 Financial Results - TipRanks
Exagen Inc. (XGN) Quarterly 10-Q Report - Quartzy
Exagen stock holds Sector Weight amid mixed 3Q24 results - Investing.com
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Exagen Inc (XGN) Q3 2024 Earnings: Revenue Misses Estimates at $12.5M, Net Loss Narrows to $5.0M - GuruFocus.com
Exagen Inc. Reports Third Quarter 2024 Results - GlobeNewswire
Exagen Q3 Revenue Hits $12.5M Despite Setbacks; YTD Performance Shows 37% Loss Reduction | XGN Stock News - StockTitan
BTIG maintains Buy rating on Exagen, target at $5 By Investing.com - Investing.com UK
Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Exagen (XGN) to Release Earnings on Tuesday - Defense World
Exagen to Announce Third Quarter 2024 Results on November 12, 2024 - GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Insider Stock Sales Prove Timely As Market Valuation Descends To US$47m - Simply Wall St
Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC - Defense World
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com
Exagen Inc. (NASDAQ:XGN) Short Interest Up 20.9% in September - MarketBeat
Octopus Energy acquires solar and storage company Exagen Group - Yahoo Finance
Octopus buys British solar and battery storage firm Exagen - Reuters
PARP Inhibitor Biomarkers Market Expected to Reach $1.75 Billion by 2031 - WhaTech
Autoimmune Disease Diagnostics Market 2024 Global Insights and Business Scenario 2031 - Newstrail
San Diego 2024 Top Tech Awards ceremony set for Sept. 26 at Snapdragon Stadium - CBS News 8
Autoimmune Disease Testing Market to Reach $12.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research - PR Newswire UK
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now - MSN
Shareholders in Exagen (NASDAQ:XGN) have lost 84%, as stock drops 12% this past week - Yahoo Finance
PARP Inhibitor Biomarkers Market to Surge with 8.8% CAGR by 2031 - WhaTech
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified - Simply Wall St
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):